Loading...
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy. Recent advances in treatment strategies f...
Na minha lista:
| Udgivet i: | BMJ Open |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6530331/ https://ncbi.nlm.nih.gov/pubmed/31092657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-026779 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|